All News

Plaquenil.HCQ_.pills_.jpg (keep)

Hydroxychloroquine Shortage During COVID-19

d Jack Cush, MD

According to a recent report in Annals of Rheumatic Disease, public enthusiasm for hydroxychloroquine (HCQ) created significant access issues for rheumatic patients in the early phases of the COVID-19 pandemic.

Read Article
Adipose fat cells

Adipose Transplants as a New Regulator of Osteoarthritis

d Jack Cush, MD

A novel report from PNAS suggests that in osteoarthritis (OA), the damage is not entirely from body weight and mechanics, instead it may be from adipose tissue itself.

Read Article
steroid prednisone lab

Corticosteroid Use Hikes CV Risks in Rheumatic Patients

d Jack Cush, MD

UK Clinical Practice Research Datalink population study shows that patients with immune-mediated inflammatory diseases, such as RA, PMR, GCA and IBD, have an augmented risk of CV outcomes with glucocorticoid use; even lower doses had a near doubling of their underlying CVD risk.

Read Article
Download your RheumaKnowledgy Card https://t.co/L7O0UFjEBV https://t.co/iFtVKERnjC

Links:

Dr. John Cush RheumNow ( View Tweet)
Corticosteroid Use Hikes CV Risks in Rheumatic Patients--It is long known that high-dose steroids may increase the risk of cardiovascular disease (CVD), heart disease, stroke, or other vascular outcomes, but it is unknown what the risk is at lower doses. https://t.co/gkTLP3ceVD https://t.co/HMpvpham1q

Links:

Dr. John Cush RheumNow ( View Tweet)
Medicare's 'Most Favored Nation' Drug-Pricing Rule in Limbo--The fate of the Trump administration's "most favored nation" (MFN) rule for bringing down prescription drug prices remains uncertain as President-elect Joe Biden prepares to assume office. https://t.co/3NnvyRiVDo https://t.co/gLSFERaNku

Links:

Dr. John Cush RheumNow ( View Tweet)
SOBI announced Kineret is now FDA approved to treat DIRA (defic of IL-1 receptor antagonist), an ultra-rare, autoinflammatory Dz caused by a genetic mutation in the IL1RN gene,. Pts have life-threatening systemic inflammation with skin and bone involvement https://t.co/iccvWYJva9

Links:

Dr. John Cush RheumNow ( View Tweet)

National Psoriasis Foundation Task Force updated their COVID-19 guidance statements. Including Guidance 4.6, stating PsA pts who receive a mRNA-COVID vaccine should continue their biologic or oral therapies as they manag of their psoriatic disease https://t.co/byujtDET33

Links:

Dr. John Cush RheumNow ( View Tweet)

Retrospective study of 171 GCA patients found that 32% had aoritis (by Sxs or AI murmur); hese pts were 6 fold more likely to have subsequent Aortic complications (aortic aneurysms or dissection) https://t.co/zRVzmnU7JH

Links:

Dr. John Cush RheumNow ( View Tweet)

After your 2 doses of COVID vaccine, YES you need to continue to wear a mask, cont. hand washing & social distancing - so as to continue to protect yourself and others. While vaccinated you can still become infected and spread infection. https://t.co/TkcSNx0hF1

Links:

Dr. John Cush RheumNow ( View Tweet)

A oatint infected with COVID-19- Yes they should get vaccinated ~90days after infection has resolved.Antibody testing is not needed before you are vaccinated. Evidence suggests that reinfection is uncommon in the 90 days after initial infection. https://t.co/TkcSNx0hF1.

Links:

Dr. John Cush RheumNow ( View Tweet)

Preprint results of the REMAP-CAP trial in the UK shows that IL-6 inhibitors, when given within 24 hrs of ICU entry for COVID-19, lowers mortality rate by 36%. Hosp mortality in 353 TCZ was 28%, 48 sarilumab was 22% in 402 controls was 36%. https://t.co/fkjOz99t0l

Links:

Dr. John Cush RheumNow ( View Tweet)

ACR Convergence 2020 Late Breaking Abstracts available from the ACR "Spotlight" slide give away. 10 slides on COVID, Tyk2 in PsA, FAST febuxostat study, Tofa in AS and novel drugs for SLE and PSS https://t.co/DvcDyusCUR

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast is up! Benlysta safety, HCQ lowers thromboses, HCQ adherence, Telemedicine, Actemra in COVID,, 2021 looking forward and zoomatology! Watch it here>> https://t.co/PtfEUPB1hc or listen to podcast on Apple> https://t.co/FHJv01AAbC or Android>https://t.co/Iylluqqeej

Links:

Dr. John Cush RheumNow ( View Tweet)

ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at #ACR20? Listen to the experts as they present their views on the top abstracts. https://t.co/r5Cf4WS63s https://t.co/N6QYsofbWe

Links:

Dr. John Cush RheumNow ( View Tweet)
Our latest podcast is up—Lights, Camera, Zoom. We review the news, journal articles and blogs featured on RheumNow this week. Download wherever podcasts are available. https://t.co/8O5AWNa88d

Links:

Dr. John Cush RheumNow ( View Tweet)

Rheumatologists: Record your question or case for the RheumNow podcast. https://t.co/NDhYNX50e2

Links:

Dr. John Cush RheumNow ( View Tweet)

Adherence to Hydroxychloroquine Lowers Lupus Mortality A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality. Read more... https://t.co/luoot7sZZl https://t.co/i2qrqU4EDy

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats – top presentations in Still’s disease Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at ACR Convergence 2020? Listen to the experts as they present their views on the top abstracts. https://t.co/MD6lU5oIvy https://t.co/wGVUI5Xjkk

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats- top presentations in nr-axSpA, AS, axial PsA and Still’s disease. Sponsored by Novartis Medical Affairs Unable to attend the key sessions at #ACR20? Listen to the experts as they weigh in on the top abstracts. https://t.co/bFrbEGtnw3 https://t.co/dMqhX0f6te

Links:

Dr. John Cush RheumNow ( View Tweet)
×